Efficacy of continuous subcutaneous insulin infusion in Type 1 diabetes: a 2‐year perspective using the established criteria for funding from a National Health Service

Abstract

CSII, commenced according to the criteria for a nationally funded clinical programme, improves glycaemic control and quality-of-life outcomes with fewer hypoglycaemic episodes in T1D subjects previously conventionally treated with MDI.